ߜ The effectiveness of in vivo suppression of neovascularization and growth of malignant glial tumors by in situ administration of an antibody directed against basic fibroblast growth factor (bFGF), a strong mitogen for cells of mesodermal origin, was tested. One hundred fifty congenitally athymic nude rats (Han rnu/rnu) were implanted intracerebrally with U-87MG tumor cells, known constitutive producers of bFGF. The animals were randomly assigned to six groups of 25 animals each. Animals were treated by in situ application of saline (Group F), control antibody (Group D), or polyclonal antibFGF antibody (Group B). In additional groups a putative effect on tumor growth caused by the treatment application device itself (between growth control Groups A and E), and the effect of heat-inactivated tumor cells (negative control Group C) were tested. After 3 weeks of treatment, tumor progression and degree of neovascularization were morphometrically recorded. In the untreated Groups A and E massive tumor growth was recorded, consisting of 19.9% Ϯ 0.4% and 27.1% Ϯ 0.5%, respectively, of the total brain cross-sectional area. In Group C, no tumor growth occurred. In control Groups D and F tumor progression consisted of 18.6% Ϯ 0.4% and 18.5% Ϯ 0.4%, respectively, of the total brain crosssectional area; whereas in the anti-bFGF treated Group B, significantly smaller tumor masses measuring 7.2% Ϯ 0.1% were recorded. New blood vessels were located both peritumorally and intratumorally and defined as numerical density and area fraction (number/area and area/area). Significantly more new blood vessels were found in Groups A, D, E, and F, ranging from 41,380/mm 2 2 intratumorally. The authors conclude that treatment with anti-bFGF antibody is effective in inhibiting tumor-induced angiogenesis and correlated tumor progression. However, owing to the character of the experimental system used, one cannot exclude the possibility that application of the specific anti-bFGF antibody also counteracts device-induced neovascularization. The authors suggest that combined surgical excision and adjuvant immunotherapy of tumors such as glioblastoma and other malignant brain tumors that express bFGF might prevent tumor recurrence.
secretion pathway used during development and differentiation by proteins such as the cytokine interleukin-1␤ (IL-1␤) and the muscle lectin L-14, both of which are devoid of secretion signals. 36, 38 Previous studies have demonstrated that heparin influences endothelial cell proliferation in a variety of ways unrelated to its anticoagulant properties. 11, 12 The majority of heparin's effects on the endothelium appear to be related to its interactions with bFGF, which binds with high affinity to heparin. In fact, both in vitro and in vivo studies have revealed that a significant proportion of cellsynthesized FGF is found outside the cells, localized within the extracellular matrix and bound to heparin-like glycosaminoglycans. These findings have led to the suggestion that matrix-associated FGF represents an extracellular reservoir that may be (partially) depleted by the action of heparan sulfate-degrading enzymes acting either during inflammation or tumor metastasis, or by heparin release from infiltrating mast cells. 11, 12 Basic fibroblast growth factor, aFGF, and the other members of the FGF gene family compete for binding to high-affinity plasma membrane receptors with tyrosine kinase activity, suggesting a general, extracellular mode of action. 54 The putative implication of bFGF in the autocrine growth of glial tumors is supported by several observations. [42] [43] [44] 46, 55 Primary human astrocytomas, gliomaderived cell lines, and schwannomas express high levels of bFGF messenger ribonucleic acid (mRNA) and contain abundant quantities of biological and immunoactive bFGF. 24, 34, 41, 48, 67 It has been reported that the malignant glioma cell line U-87MG expresses high levels of bFGF mRNA and both contains 44 and secretes 55 bFGF. However, although bFGF was found to stimulate the growth of astrocytes in culture, it did not stimulate the growth of U-87MG cells and, furthermore, an anti-FGF antiserum had no effect on growth inhibition in these cells. 45 It is known that the expression level of the bFGF peptide increases proportionally with the degree of tumor malignancy. 61 Because growth of solid tumors is dependent on angiogenesis 18 and the formation of new blood vessels is strongly induced by bFGF, inhibition of bFGF may provide a novel means of treating malignant glial tumors 17, 30, 62 by interrupting their autocrine and paracrine pathways.
In the present experiments, we established a brain-specific and reproducible in vivo model for malignant glial tumor-induced neovascularization so that we could study the role of bFGF within malignant tumor progression and the effect of its antibody-mediated inhibition. In this article we report our findings on the effect on tumor growth achieved by using anti-bFGF as an antiangiogenic factor antibody.
Materials and Methods

Tumor Cell Cultures and Preparation of Implants
The human glioma cell line U-87MG* was cultured ( Fig. 1 ) in T25 culture flasks in RPMI 1640 medium supplemented with 10% fetal calf serum and the cells were allowed to multiply exponentially. Cell samples were tested for contamination with Mycoplasma and their viability was assessed using the 0.4% Trypan blue exclusion test. Cells were harvested by trypsinization in ethylenediaminetetraacetic acid/Trypsin for 5 minutes at 37˚C, washed in phosphate-buffered saline, and centrifuged at 200 G several times. After cell density was determined, the cells were brought into suspension at a final concentration of 4 ϫ 10 6 /ml and kept on ice until injection.
Surgical Assay
One hundred fifty congenitally athymic, adult male and female nude rats (Han rnu/rnu) † weighing 200 to 240 g were kept initially in groups of two or three, housed in sterile cages, and given free access to autoclaved food and water. Stereotactic surgery was performed under sterile conditions. A stereomicroscope ‡ with a total magnification of ϫ 6.3 to ϫ 40 was used during surgical procedures. After intraperitoneal administration of anesthesia was accomplished using xylocaine (100 mg/kg body weight (BW)) supplemented with ketamine (60 mg/kg BW), a 1.5-mm burr hole was drilled over the right parietal lobe of the rat, 2 mm to the right of the sagittal suture (Fig. 2) . After reflection of the periosteum a siliconized polyethylene device (cross diameter 8 mm, height 6 mm) was affixed to the skull using histoacryl, to be used for later injections in the treated animals to minimize tissue damage. Initially 50 l U-87MG cell suspension containing 2 ϫ 10 5 cells was slowly injected intracortically through a 26-gauge needle adapted to the device (Fig. 2) , at a depth of 2 mm. Subsequently, the device's opening was sealed with a droplet of bone wax to prevent reflux and the skin was sutured. The experimental phase took 3 weeks. Six groups of 25 animals each were randomly formed. Three groups, labeled B, D, and F, were treated during this period twice a week, whereas the other three groups, labeled A, C, and E, remained untreated (Table 1) .
Treatment Protocol
Lyophilized rabbit polyclonal anti-bFGF antibody and rabbit polyclonal control immunoglobulin G (IgG) § were kept at 4˚C until use. Both antibodies were reconstituted under sterile conditions according to the manufacturer's instructions. Protein concentrations were determined by absorbance at 280 nm, and both solutions were adjusted to 1 mg/ml to obtain equal antibody concentrations. Once reconstituted, the entire solution of a vial was used during a treatment session. Animals were anesthetized immediately before treatment. The animals in Groups B, D, and F received treatment twice a week over a period of 3 weeks, with anti-bFGF, control IgG, or isotonic saline (Table 1 ). In Groups B and D, treatment began at the time of U-87MG implantation with an initial dose of 33 g antibFGF or 33 g control IgG, each contained in the 50-l cell suspension ( Table 1) .
The neutralizing activity of the anti-bFGF antibody was determined by the manufacturer by blocking studies of bFGF on bovine endothelial cells. Both antibodies, that is, anti-bFGF and control IgG, were tested in [ 3 H]thymidine uptake assays for cytotoxic effects on U-87MG cells (Fig. 3) . During the period of treatment, animals were inspected daily to determine neurological disorders. The animals that died during the perioperative phase were not taken into account for the final evaluation ( Table 1 ). The animals that died during the experiments did so primarily during the perioperative phase (Day 0) or shortly thereafter (Days 2 or 3), as shown in Results, Survival Characteristics. The brains from these animals were processed in the same manner as those from the surviving animals (that is, by fixation, dehydration, and paraffin embedding).
Preparation of Histological Samples and Staining
After 3 weeks all surviving animals were sacrificed and their brains were removed and fixed by an in situ perfusion using a 4% Tris-buffered formalin solution (10 g Tris/L, 4% formalin). The brains were subsequently dissected under the same stereomicroscope used for the tumor implantation and cut into slices of 2-mm thickness. Further fixation in formalin was conducted over a 2-day period. The brain slices were dehydrated using 50%, 70%, 90%, and 100% ethanol. After treatment with acetone, the slices were embedded in paraffin (melting point 56˚ to 58˚C) and 5-m sections were cut. For each animal, we examined five separate samples. Routine histological studies of consecutive slices were performed using hematoxylin and eosin and trichrome staining.
For immunocytochemical studies, the sections were first digested for 10 minutes at 37˚C with pronase E solution (1 ml pronase E/ml Tris-buffered saline). To detect the production of bFGF by the tumors, the glial reaction, and the degree of neovascularization, immunostaining was performed for bFGF, glial fibrillary acid protein (GFAP), and factor VIII using rabbit anti-bovine bFGF, rabbit anti-cow, and rabbit anti-human von Willebrand factor, respectively, using a subsequent peroxidase-antiperoxidase technique. To attain the best identification and measurement of blood vessels, immunohistochemical studies for factor VIII were performed without counterstaining. Finally, the specimens were covered using an aqueous mounting medium.
Morphometrical Analysis and Quantification
The U-87MG implants grew as solid, spheroidal tumors, sharply delineated against host brain tissue. Consecutive slices, cut at 5 m each were evaluated microscopically to detect the greatest planar extension of the tumor. A charge-coupled device color camera* adapted to the same microscope used for tumor implantation, was used for this purpose. After previous calibration using a standard microslide, slices stained with trichrome were digitalized by means of a computer software program † at a total magnification of ϫ 6.3. Tumor and brain surfaces within the same slice were traced in square millimeters. Tumor progression (tumor growth) was traced as the percentage of the quotient TUMOR SURFACE (mm 2 )/ BRAIN SURFACE (mm 2 ) ϫ 100 (Fig. 4A) . Immunostained slices that were not counterstained (factor VIII) were used for the quantification of blood vessels.
Calibration and digitalization were performed, in the described manner, using an additional microscope with adapted charge-coupled device camera, at a total magnification of ϫ 100. The degree of neovascularization was measured both peritumorally within a 570-m broad band surrounding the tumor, defined as the region of maximum neovascularization, and intratumorally within the whole tumor surface. The degree of neovascularization was determined as: N CAPILLARIES /PERITUMORAL BAND SURFACE (mm 2 ) and N CAPILLARIES /TUMOR SURFACE (mm 
______________
Rabbit anti-bovine bFGF was obtained from Sigma Aldrich Vertriebs GmbH, Deisenhofen, Germany; rabbit anti-cow and rabbit anti-human von Willebrand factor were obtained from Dako Diagnostika GmbH, Hamburg, Germany.
* Charge-coupled device camera obtained from Sony Deutschland GmbH, Broadcast & Communication, Köln, Germany.
† Stained slices were digitalized using the Autoscope software package available from Digithurst, Nürnberg, Germany. ) ϫ 100, respectively ( Fig. 4C and E) . The reactive capillaries sprouting around the injection hole in Group C were used as a correction factor for the peritumoral neovascularization; that is, they were subtracted from the values within all other groups because they were also found in animals having no tumor formation.
Statistical Analysis
Statistical analysis was performed using a standard computer software package; ‡ the variables were defined as shown in Tables 2  and 3 . The multivariate analysis of variance (MANOVA) was used to compare changes in tumor progression and both peritumoral and intratumoral neovascularization between treated animals (Groups B, D, and F) and control animals (Groups A, C, and E). (Table 2) . Data were pooled from animals within the same group. T-tests (least significant difference; LSD) were performed for each variable with LSD equal to 0.2433. Statistical significance was established at p less than 0.05 (Table 3) .
Results
Survival Characteristics
From the total of 150 nude rats implanted with the U-87MG cells differing numbers survived throughout the groups (Table 1 ). In no case was an infection or hemorrhage the cause of death. As the macroscopic and microscopic inspections of the brains revealed, edema was the primary reason for death. The animals that died in Groups B through F did so mainly during the perioperative phase (Day 0) or shortly thereafter (Days 2 or 3) . The animals were inspected daily and the only symptoms observed were increased intracranial pressure leading to rapid (1 to 2 hours) neurological deterioration with decerebrate rigidity, followed by death. Because of the very short time between tumor cell implantation and death, only the smallest tumor clusters could be observed histologically in the nonsurviving animals from Groups B, D, E, and F. Because taking those tumors into account would have corrupted the interpretation of findings after a standardized period of therapy (that is, 3 weeks), these animals have been excluded from our findings.
Tumor Progression
Massive tumor growth with midline shift and compression of the side ventricle could be observed in the untreated Groups A and E (Fig. 5A) . On the contrary, no tumor growth occurred in Group C (Fig. 5C ), in which animals were implanted with heat-inactivated U-87MG cells. In the cross sectional area tumor extension reached 19.9% Ϯ 0.4% in Group A and 27.1% Ϯ 0.5% in Group E, whereas in the anti-bFGF antibody-treated Group B, significantly smaller tumor masses were identified (Fig. 5B ) with a surface extension of 7.2% Ϯ 0.1% (Fig. 4A) . No significant difference was found between control Groups D (control IgG treatment) and F (saline) with tumor extensions measuring 18.6% Ϯ 0.4% and 18.5% Ϯ 0.4%, respectively, but significant difference was found between these groups and the control Groups A and E, as well as the specifically treated Group B (Fig. 4A and Table 3 ).
Detection of bFGF
With the exception of Group C, high levels of bFGF were detected in the tumor cells, but not in the surrounding brain tissue. There was no visible difference in the staining patterns of the tumors between the groups, as identified by means of light microscopy because the amounts of detectable bFGF were not quantified by densitometry. Detection of intratumoral bFGF, as revealed by immunostaining, was similar in all groups except for Group C. In these groups, no significant difference in the amount of intratumoral bFGF protein could be observed. The exposure to the anti-bFGF antibody led to a depletion of mitogenically active bFGF protein in the extracellular matrix within the tumor tissue by forming mitogenically inactive immunocomplexes. However, because the antibFGF antibody does not penetrate cell membranes and exhibits no cytotoxic effects, staining intensity within tumor cells remained constant.
Angiogenesis Induced by bFGF
With the exception of Group C (heat-inactivated U-87MG cells) and Groups A and E (growth controls), all animals received treatment throughout the 3 weeks via the polyethylene device affixed to the skull. In Groups A, D, E, and F a high degree of neovascularization was apparent both peri-and intratumorally (Fig. 5D) , reaching a maximum in Group E. In the anti-bFGF antibody-treated Group B a significantly lower degree of neovascularization was seen (Fig. 5E ) as compared to the controls. Significant differences in the degree of neovascularization were found between the groups except between Groups D and F (Table 3) . In Group C, reactive blood vessels sprouting around the injection hole were found but no tumor growth because the animals in this group received heatinactivated U-87MG cells (Fig. 5F ). The reactive blood vessels in Group C were quantified in the same manner as for all other groups, but interpreted as a response to physical tissue damage rather than to tumor cells. These reactive blood vessels were subtracted from the peritumoral ones in the remaining groups to obtain an accurate value for bFGF-induced angiogenesis (Tables 2 and 3) .
Effect of Treatment on Animal Weight
No significant difference in body weight could be demonstrated between animals in the treated and untreated groups and no significant difference was found between animal weights at the beginning and end of the experimental phase. Because morphometrical analysis of tumor progression and neovascularization was performed as planar measurements and not as stereological evaluations, brain weight was not taken into account.
Discussion
Role of bFGF in Autocrine and Paracrine Tumor Growth
Basic fibroblast growth factor is a polypeptide that exerts mitogenic activity on many cells of mesodermal and neuroectodermal origin, the latter including glial cells. It has been demonstrated that the human malignant glioma cell line U-87MG expresses in vitro high steady-state levels of the bFGF mRNA, contains abundant stores of bFGF, and secretes biologically active bFGF protein. [42] [43] [44] 46, 55 The expression of mRNAs for both bFGF and the bFGF receptor suggests the existence of an autocrine loop, propagating uncontrolled growth of these cells. 45 Other established glioma cell cultures such as C6, T98-G, or SNB-18 cells 24, 42, 56, 66 are also able to express both the bFGF protein and high-as well as low-affinity binding sites. As indicated by several authors, probably all human glioblastoma multiforme cell lines underlie this autocrine loop by coexpressing bFGF and its high-affinity receptor flg. 3, 25, 40, 41 Tumor progression is not only dependent on self stimulation via autocrine pathways but also on continuous angiogenesis within the tumor and the area surrounding the tumor, 17 an event that occurs simultaneously with tumor progression, through the stimulation of endothelial cells by angiogenic factors like bFGF. In particular, endothelial cells have been shown to express two classes of FGF-binding sites: low-abundance high-affinity receptors mediating the biological activity, as well as high-abundance, low-affinity binding sites, although the physiological relevance of the latter is not yet clear. 11, 12 These findings suggest an important role for bFGF during tumor progression and tumor-induced neovascularization, leading to the conclusion that agents that inhibit angiogenesis may potentially inhibit tumor growth. 9, 10, 18, 31, 63 Although attention has focused primarily on malignant tumors as highly angiogenic, 3, 60, 62, 67 angiogenesis can also be induced by benign tumors, and the degree of neovascularization may correlate with their progression.
32,49
Thus, all tumors are potential targets for therapy with antiangiogenic factors.
Different means of antiangiogenic treatment have been proposed for tumor therapy, ranging from chemical blocking of the bFGF protein 50, 63 and inhibition of the bFGF protein transcription, 45 to antibody inhibition of the bFGF protein 26 or concurrent antagonists. 7 Because bFGF is one of the most potent angiogenic factors, inhibition of the bFGF protein in vivo by specific antibodies may prove to be a promising therapy for human malignant glioma. In our experiments, we showed in vivo blocking of neovascularization and correlated tumor growth by a specific anti-bFGF antibody. Tumor growth inhibition, as well as inhibition of neovascularization, most likely occurred through immunodepletion of the bFGF produced by the U-87MG tumor cells, interrupting autocrine as well as paracrine loops, including the angiogenic response of the endothelial cells. The in vitro blocking studies on cultures of U-87MG cells clearly demonstrated that autocrine growth mechanisms do not play an important role in tumor growth in this model. Therefore we conclude that the inhibitory effects are mainly due to interruption of paracrine loops.
Control Groups
We demonstrated that application of an irrelevant IgG did not influence the growth of the tumor. Tumors in this group (D) grew to dimensions similar to those in the saline-treated animals (Group F), although differences could be found when comparing them to Groups A and E. This fact seems to be due solely, and in a similar manner, to a dilution effect that both the irrelevant antibody (IgG) and the saline exerted on bFGF. A putative effect of the polyethylene device on tumor growth has to be considered. Tumors implanted with the device that were not treated (Group E) grew significantly larger and exhibited the highest degree of neovascularization of all groups. This unexpected observation is possibly due to an intrinsic effect of the device itself. Such an effect could be explained as a chronic irritation of the tumor cells associated with a "boost" release of tumor growth-promoting cytokines. Such a chronic irritation could be one possible explanation for short-time recurrences of glioblastoma multiforme after subtotal neurological surgery. Because local exposure to therapeutics like cytostatica following neurological surgery mostly occur, for example, through an Ommaya reservoir, such intrinsic side effects have to be taken into account. This could also explain the lack of tumor disappearance in Group B in our experiments. Both saline and control IgG appeared to neutralize these intrinsic effects because these control groups had tumors comparable to those in animals without the device.
There has been no systematic investigation regarding such side effects as tumor growth (or recurrence)-promoting or -accelerating actions of chronic irritation on malignant brain tumor cells. However, a few clinical observations clearly indicate that methods of adjuvant therapy to neurosurgery, such as brachytherapy, in some cases promote tumor recurrence, although at a distance from the primary site. 39 Similar effects could be observed in some cases of interstitial brachytherapy with iridium seeds ( 192 Ir) using stereotactic implantation of afterloading catheters in patients with recurrent or unremovable malignant gliomas. 33 Complications (massive brain edema with fatal outcome) during interstitial thermoradiotherapy or hyperthermia induced by ferromagnetic implants for high-grade supratentorial gliomas have also been reported. 59 However, the most striking effects regarding tumor growth progression observed in those cases (up to nine of 20 patients) were adjuvant therapy that occurred through an Ommaya reservoir, accompanied by a massive reaction at the tip of the connected catheter as well as dense tumor layers with capillary hyperplasia at the surface of the tumor cavity. 15, 47 In our study, we clearly demonstrated that the application of the anti-bFGF antibody effectively inhibited tumor growth progression 2.7 to 3.8 times (when comparing Group B with Groups A, D, E, and F), inhibiting as well tumor-induced neovascularization, and it also compensated the tumor growth-promoting effect of the silicon device used for the antibody application.
Clinical Relevance of Anti-bFGF Therapy
Glioblastomas and anaplastic astrocytomas are highly malignant brain tumors and are among the most neovascularized solid tumors. Because bFGF lacks a signal sequence it is not secreted via the classic secretory pathway. 35 Thus, externalization of bFGF may be fulfilled through exocytosis, a mechanism and alternative secretion pathway independent of the endoplasmic reticulum-Golgi complex, which is used during development and differentiation by proteins such as the cytokine IL-1␤ and the muscle lectin L-14, both of which are devoid of secretion signals.
36,38 It has been suggested that this growth factor may be also released from dead or damaged cells. This occurs often in necrobiotic areas of rapidly growing tumors like glioblastoma. Immunotherapy with an antibFGF antibody appears to have significant relevance, although angiogenesis is not simply controlled by the presence of bFGF but is mediated by a balance of several angiogenic inducers and inhibitors. 4, 57 In addition, other angiogenic factors, such as vascular endothelial growth factor or platelet-derived growth factor, may complement the actions of bFGF in glial neoplasia. 28, 29, 52, 53 In our model, we demonstrated that application of an anti-bFGF antibody suppressed tumor growth and inhibited angiogenesis. A combination of this new biological approach with surgical tumor excision might prevent tumor recurrence. However, owing to the character of the experimental system used, one cannot exclude the possibility that the application of the specific anti-bFGF antibody also counteracts the observed device-induced neovascularization. 
